Symbol="XNCR"
AssetType="Common Stock"
Name="Xencor Inc"
Description="Xencor, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of cytokine and monoclonal antibody therapies designed to treat cancer patients and autoimmune diseases in the United States and internationally. The company is headquartered in Monrovia, California."
CIK="1326732"
Exchange="NASDAQ"
Currency="USD"
Country="USA"
Sector="LIFE SCIENCES"
Industry="PHARMACEUTICAL PREPARATIONS"
Address="111 WEST LEMON AVE, MONROVIA, CA, US"
FiscalYearEnd="December"
LatestQuarter="2023-06-30"
MarketCapitalization="1372890000"
EBITDA="-155264992"
PERatio="None"
PEGRatio="0"
BookValue="11.2"
DividendPerShare="0"
DividendYield="0"
EPS="-2.15"
RevenuePerShareTTM="1.894"
ProfitMargin="-1.125"
OperatingMarginTTM="-1.453"
ReturnOnAssetsTTM="-0.126"
ReturnOnEquityTTM="-0.179"
RevenueTTM="113394000"
GrossProfitTTM="-34984000"
DilutedEPSTTM="-2.15"
QuarterlyEarningsGrowthYOY="0"
QuarterlyRevenueGrowthYOY="0.509"
AnalystTargetPrice="44.08"
TrailingPE="-"
ForwardPE="-"
PriceToSalesRatioTTM="5.57"
PriceToBookRatio="2.365"
EVToRevenue="3.879"
EVToEBITDA="19.03"
Beta="0.719"
num_52WeekHigh="38.2"
num_52WeekLow="22.17"
num_50DayMovingAverage="23.98"
num_200DayMovingAverage="27.79"
SharesOutstanding="60391000"
DividendDate="None"
ExDividendDate="None"
symbol="XNCR"
open="22.67"
high="22.91"
low="22.35"
price="22.64"
volume="219243.00"
latest_trading_day="2023-08-30"
previous_close="22.73"
change="-0.09"
change_percent="-0.3960%"
aroon_positive_momentum_days="0"
aroon_negative_momentum_days="100"
trend_strength="Absent or Weak Trend"
buying_signal="Strong Sell Signal"
volume_analysis="Target Volume"
value_analysis="Expected Range"
Aroon_change="FALSE"
Aroon_momentum="0"
Volume_recent_avg="296683"
Change_recent_avg="-0.08"
Delta_recent_avg="0.81"
Variance_recent_avg="0.4"
Change_ratio_recent_avg="-0.33"
RSI_change="FALSE"
ADX_change="FALSE"
Aroon_signal="negative"
Aroon_change="FALSE"
Aroon_momentum_positive="0"
Aroon_momentum_negative="100"
image_negative_thumbnail_id_1="1097"
image_negative_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Negative_Landscape_0130.jpeg"
image_negative_thumbnail_id_2="120"
image_negative_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/05/MI_Finance_Negative_Landscape_0056.jpeg"
image_neutral_thumbnail_id_1="575"
image_neutral_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Neutral_Landscape_0024.jpeg"
image_neutral_thumbnail_id_2="583"
image_neutral_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Neutral_Landscape_0016.jpeg"
image_positive_thumbnail_id_1="994"
image_positive_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Positive_Landscape_0156.jpeg"
image_positive_thumbnail_id_2="957"
image_positive_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Positive_Landscape_0119.jpeg"
image_professor_thumbnail_id_1="1197"
image_professor_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Professor_Landscape_0031.jpeg"
image_professor_thumbnail_id_2="1202"
image_professor_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Professor_Landscape_0036.jpeg"
